Top

Published in:

01-10-2011

Review of the Microscopic Colitides

Authors: Eugene F. Yen, Darrell S. Pardi

Published in: Current Gastroenterology Reports | Issue 5/2011

Abstract

Microscopic colitis is a common cause of chronic diarrhea in predominantly older adults. Incidence rates of microscopic colitis (including lymphocytic and collagenous colitis) have increased over time to levels comparable to other forms of inflammatory bowel disease. The possibility of drug-induced microscopic colitis is an important consideration when evaluating these patients, although this concept requires further investigation. There are few controlled treatment trials in microscopic colitis, with much of the data on treatment coming from retrospective studies. In patients with microscopic colitis, a systematic approach to therapy often leads to satisfactory control of symptoms. In this review, we will provide an updated assessment of the epidemiology, diagnosis, and treatment of microscopic colitis.

Pardi DS, Loftus Jr EV, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56:504–8.PubMedCrossRef

Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94:418–23.PubMed

Williams JJ, Kaplan GG, Makhija S, et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol. 2008;6:35–40.PubMedCrossRef

Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef

Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175–81.PubMedCrossRef

• Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 105:859–65. The first study to prospectively evaluate the yield of colonoscopy in patients with irritable bowel syndrome symptoms, with 2.3% of patients over age 45 being diagnosed with microscopic colitis.

Yen EF, Pokhrel B, Bianchi LK, et al. Concomitant adenoma rates in patients with microscopic colitis. Gastroenterology. 2009;136:A-20.CrossRef

Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004;53:536–41.PubMedCrossRef

Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci. 2002;47:1122–8.PubMedCrossRef

10.

Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis in Orebro, Sweden, an epidemiological study 1984–1993. Gut. 1995;37:394–7.PubMedCrossRef

11.

Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996;39:846–51.PubMedCrossRef

12.

Gremse DA, Boudreaux CW, Manci EA. Collagenous colitis in children. Gastroenterology. 1993;104:906–9.PubMed

13.

Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis. 2005;20:312–6.PubMedCrossRef

14.

• Hjortswang H, Tysk C, Bohr J, et al. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis. 2010;43:102–9. A cross sectional study with 116 patients with collagenous colitis, the first major paper to illustrate the extent of quality of life impairment in patients with microscopic colitis. PubMedCrossRef

15.

Baert F, Wouters K, D’Haens G, et al. Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut. 1999;45:375–81.PubMedCrossRef

16.

• Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002;123:978–84.PubMedCrossRef

17.

• Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut. 2003;52:248–51.PubMedCrossRef

18.

• Baert F, Schmit A, D’Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology. 2002;122:20–5.PubMedCrossRef

19.

• Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology. 2009;136:2092–100. The preceding four studies (16–19) represent the largest randomized placebo-controlled studies to date on the treatment of microscopic colitis, all using budesonide. PubMedCrossRef

20.

• Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2008;135:1510–6.PubMedCrossRef

21.

• Bonderup OK, Hansen JB, Teglbjaerg PS, et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut. 2009;58:68–72. The preceding 2 studies are placebo-controlled studies involving budesonide for maintenance of remission in microscopic colitis. PubMedCrossRef

22.

Chan JL, Tersmette AC, Offerhaus GJ, et al. Cancer risk in collagenous colitis. Inflamm Bowel Dis. 1999;5:40–3.PubMedCrossRef

23.

Kao KT, Pedraza BA, McClune AC, et al. Microscopic colitis: a large retrospective analysis from a health maintenance organization experience. World J Gastroenterol. 2009;15:3122–7.PubMedCrossRef

24.

Pardi DS, Ramnath VR, Loftus Jr EV, et al. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2002;97:2829–33.PubMedCrossRef

25.

Wolber R, Owen D, Freeman H. Colonic lymphocytosis in patients with celiac sprue. Hum Pathol. 1990;21:1092–6.PubMedCrossRef

26.

Green PH, Yang J, Cheng J, et al. An association between microscopic colitis and celiac disease. Clin Gastroenterol Hepatol. 2009;7:1210–6.PubMedCrossRef

27.

Bohr J, Tysk C, Yang P, et al. Autoantibodies and immunoglobulins in collagenous colitis. Gut. 1996;39:73–6.PubMedCrossRef

28.

Fine KD, Do K, Schulte K, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol. 2000;95:1974–82.PubMedCrossRef

29.

Pardi DS, Loftus Jr EV, Kammer PP, et al. Collagenous colitis, but not lymphocytic colitis, is associated with cigarette smoking [abstract]. Am J Gastroenterol. 2004;99:S116.CrossRef

30.

Pokhrel B, Witt B, Bianchi LK, et al. Microscopic colitis and association with cigarette smoking and alcohol intake [abstract]. Am J Gastroenterol. 2009;104:S453–4.

31.

Jarnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109:449–55.PubMedCrossRef

32.

Mosnier JF, Larvol L, Barge J, et al. Lymphocytic and collagenous colitis: an immunohistochemical study. Am J Gastroenterol. 1996;91:709–13.PubMed

33.

Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis—proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22:277–84.PubMedCrossRef

34.

Fernandez-Banares F, Esteve M, Espinos JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102:324–30.PubMedCrossRef

35.

Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut. 1992;33:683–6.PubMedCrossRef

36.

Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832–47.PubMed

37.

Yagi K, Nakamura A, Sekine A, et al. Nonsteroidal anti-inflammatory drug-associated colitis with a histology of collagenous colitis. Endoscopy. 2001;33:629–32.PubMedCrossRef

38.

Al-Ghamdi MY, Malatjalian DA, Veldhuyzen van Zanten S. Causation: recurrent collagenous colitis following repeated use of NSAIDs. Can J Gastroenterol. 2002;16:861–2.PubMed

39.

Pascua MF, Kedia P, Weiner M, et al. Microscopic colitis and medication use. Gastroenterology. 2009;136:A-366.CrossRef

40.

Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403–7.PubMedCrossRef

41.

Lundberg JO, Herulf M, Olesen M, et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest. 1997;27:869–71.PubMedCrossRef

42.

Olesen M, Middelveld R, Bohr J, et al. Luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis. Scand J Gastroenterol. 2003;38:66–72.PubMedCrossRef

43.

Perner A, Andresen L, Normark M, et al. Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut. 2001;49:387–94.PubMedCrossRef

44.

Burgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123:433–43.PubMedCrossRef

45.

Marteau P, Lavergne-Slove A, Lemann M, et al. Primary ileal villous atrophy is often associated with microscopic colitis. Gut. 1997;41:561–4.PubMedCrossRef

46.

Ung KA, Gillberg R, Kilander A, et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut. 2000;46:170–5.PubMedCrossRef

47.

Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523–6.PubMedCrossRef

48.

Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–11.PubMedCrossRef

49.

Aigner T, Neureiter D, Muller S, et al. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology. 1997;113:136–43.PubMedCrossRef

50.

Salas A, Fernandez-Banares F, Casalots J, et al. Subepithelial myofibroblasts and tenascin expression in microscopic colitis. Histopathology. 2003;43:48–54.PubMedCrossRef

51.

Lee E, Schiller LR, Vendrell D, et al. Subepithelial collagen table thickness in colon specimens from patients with microscopic colitis and collagenous colitis. Gastroenterology. 1992;103:1790–6.PubMed

52.

Couto G, Bispo M, Barreiro P, et al. Unique endoscopy findings in collagenous colitis. Gastrointest Endosc. 2009;69:1186–8.PubMedCrossRef

53.

• Carmack SW, Lash RH, Gulizia JM, et al. Lymphocytic disorders of the gastrointestinal tract: a review for the practicing pathologist. Adv Anat Pathol. 2009;16:290–306. A thorough update of the etiologies of lymphocytic infiltration in the GI tract, reviewing that intra-epithelial lymphocytes can be associated with conditions other than microscopic colitis. PubMedCrossRef

54.

Fine KD, Lee EL, Meyer RL. Colonic histopathology in untreated celiac sprue or refractory sprue: is it lymphocytic colitis or colonic lymphocytosis? Hum Pathol. 1998;29:1433–40.PubMedCrossRef

55.

Matteoni CA, Wang N, Goldblum JR, et al. Flexible sigmoidoscopy for the detection of microscopic colitis. Am J Med. 2000;108:416–8.PubMedCrossRef

56.

Tanaka M, Mazzoleni G, Riddell RH. Distribution of collagenous colitis: utility of flexible sigmoidoscopy. Gut. 1992;33:65–70.PubMedCrossRef

57.

Thijs WJ, van Baarlen J, Kleibeuker JH, et al. Microscopic colitis: prevalence and distribution throughout the colon in patients with chronic diarrhoea. Neth J Med. 2005;63:137–40.PubMed

58.

Yen EF, Hall CR, Witt B. Yield of sigmoid and rectal biopsies in the detection of microscopic colitis. Gastroenterology. 2010;138:S638.

59.

Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology. 1998;114:29–36.PubMedCrossRef

60.

Fernandez-Banares F, Esteve M, Salas A, et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci. 2001;46:2231–8.PubMedCrossRef

61.

Calabrese C, Fabbri A, Areni A, et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol. 2007;22:809–14.PubMedCrossRef

62.

Abdalla AA, Faubion WA, Loftus Jr EV, et al. The natural history of microscopic colitis treated with corticosteroids [abstract]. Gastroenterology. 2008;134:A121.CrossRef

63.

Munck LK, Kjeldsen J, Philipsen E, et al. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol. 2003;38:606–10.PubMedCrossRef

64.

Pardi DS, Loftus Jr EV, Tremaine WJ, et al. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001;120:1483–4.PubMedCrossRef

65.

Rodriguez E, Mahadevan U. Anti-TNF therapy for refractory microscopic colitis. Gastroenterology. 2009;136:A663.CrossRef

66.

Jarnerot G, Bohr J, Tysk C, et al. Faecal stream diversion in patients with collagenous colitis. Gut. 1996;38:154–5.PubMedCrossRef

67.

Williams RA, Gelfand DV. Total proctocolectomy and ileal pouch anal anastomosis to successfully treat a patient with collagenous colitis. Am J Gastroenterol. 2000;95:2147.PubMedCrossRef

Title: Review of the Microscopic Colitides
Authors: Eugene F. Yen
Darrell S. Pardi
Publication date: 01-10-2011
Publisher: Current Science Inc.
Published in: Current Gastroenterology Reports / Issue 5/2011
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-011-0207-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

The Mantra of Mucosal Healing

Food Poisoning and Diarrhea: Small Intestine Effects

Hepatobiliary Complications of Inflammatory Bowel Disease

Update on the Management of Ulcerative Colitis

Update on the Management of Crohn’s Disease

Differentiating Food Allergies from Food Intolerances

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials